Review: The choice and cardiovascular safety of particular nonsteroidal anti-inflammatory drugs

Open access

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are authorized for the relief of pain and inflammation in a wide range of conditions including the discomfort associated with headaches, osteoarthritis, rheumatoid arthritis, and menstrual pain and are available by prescription or over-the-counter (OTC). We reviewed common adverse effects of NSAIDs (especially those related to cardiovascular [CV] system) along with NICE (National Institute for Health and Care Excellence), EMA (European Medicines Agency), and the FDA (U.S. Food and Drug Administration) guidelines for safe and effective use of particular NSAIDs. Furthermore, we examined the NSAIDs market in Lithuania in a period between June 2016 and May 2017 and discussed how well recommendations mentioned above were followed. We emphasized that there was a high percentage of diclofenac prescribed in Lithuania while international guidelines encourage prescribing ibuprofen or naproxen for their relatively lower CV risk. Reviewing past trials, we observed that despite existing guidelines no single NSAID could be considered to be the safest one due to a lack of superiority trials

[1] European Medicines Agency. New safety advice for diclofenac 2013;2013.

[2] U. S. Food and Drug Administration. FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015.

[3] National Institute for Health and Care Excellence. Non-steroidal anti-inflammatory drugs. NICE Guideline (KTT13) 2017.

[4] PLLC “SoftDent”. Drug sales data 2015-2017. 2017.

[5] Borazan NH, Furst DE. Nonsteroidal Anti-Inflamatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout. In: Katzung BG, Trevor AJ, editors. Basic & Clinical Pharmacology, 13th Ed. McGraw-Hill Medical; 2015; p. 618-641.

[6] Mullan J,Weston KM, Bonney A, Burns P, Mullan J, Rudd R. Consumer knowledge about over-the-counter NSAIDs: they don’t know what they don’t know. Aust Nz J Publ Heal 2017;41(2):210-214.

[7] Fine M. Quantifying the impact of NSAID-associated adverse events. Am J Manag C 2013; 9(14 Suppl):s267-72.

[8] Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current perspectives in NSAID-induced gastropathy. Mediat Inflamm 2013;2013.

[9] Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet 2013;382(9894):769-779.

[10] Bello AE, Holt RJ. Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. Drug Safety 2014;37(11):897.

[11] Perazella MA, Luciano RL. Review of select causes of druginduced AKI. Expert Rev Clin Phar 2015;8(4):367-371.

[12] Grosser T, Ricciotti E, FitzGerald GA. The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs. Trends Pharmacol Sci 2017;38(8):733-748.

[13] Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther 2016;42(1):27-38.

[14] Anwar A, Anwar IJ, Delafontaine P. Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs. Trends Cardiovas Med 2015;25(8):726-735.

[15] Patrono C. Cardiovascular effects of nonsteroidal antiinflammatory drugs. Curr Cardiol Rep 2016;18(3):25-25.

[16] Ungprasert P. NSAIDs and cardiovascular disease: time to say no to diclofenac. Intern Emerg Med 2016;11(1):1.

[17] Danelich IM, Wright SS, Lose JM, Tefft BJ, Cicci JD, Reed BN. Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. Pharmacotherapy 2015;35(5):520-535.

[18] Lapi F, Piccinni C, et al. Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Intern Emerg Med 2016;11(1):49.

[19] McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006;296(13):1633-44.

[20] Varas-Lorenzo C, Riera-Guardia N, et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidem Dr S 2011;20(12):1225-1236.

[21] Medicines and Healthcare products Regulatory Agency. Diclofenac: new contraindications and warnings. 2013.

[22] McGettigan P, Henry D. Use of non-steroidal antiinflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10(2):e1001388.

[23] van Walsem A, Pandhi S, et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther 2015;17(1):66.

[24] Kearney PM, Baigent C, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332(7553):1302-1308.

[25] Trelle S, Reichenbach S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.

[26] McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8(9):e1001098.

[27] Arfè A, Scotti L, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857.

[28] Bally M, Dendukuri N, et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909.

[29] Nissen SE, Yeomans ND, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. New Engl J Med 2016;375:2519-2529.

[30] Sondergaard KB, Weeke P, et al. Non-steroidal antiinflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J-Card Pharm 2016;3(2):100-107.

[31] European Medicines Agency. Updated advice on use of high-dose ibuprofen 2015. 2015.

[32] European Medicines Agency. PRAC recommends updating advice on use of high-dose ibuprofen. 2015.

[33] National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. NICE Guideline (CG183) 2014.

[34] National Institute for Health and Care Excellence. Fractures (non-complex): assessment and management. NICE Guideline (NG38) 2016;1.1.6:4.

[35] National Institute for Health and Care Excellence. Low back pain and sciatica in over 16s: assessment and management. NICE Guideline (NG59) 2016.

[36] National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management. NICE Guideline (CG182) 2015.

Seminars in Cardiovascular Medicine

The Journal of Lithuanian Heart Association

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 344 344 39
PDF Downloads 294 294 25